Skip to content

Psychedelic Medicine

ISSN 2831-4425, 2831-4433

113 papers in the library · 717 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users.

Psychedelic Medicine March 1, 2025 Daniel J. Kruger, Jacob S. Aday, Christopher W Fields et al. 19 citations

Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy. There is a surge of interest in psychedelics, and psychedelic-assisted psychotherapy is becoming increasingly accessible. However, most individuals using psychedelics do so outside of therapeutic contexts. It is important to understand the adverse...

DOI: 10.1089/psymed.2024.0011 (opens in new tab) Full text (opens in new tab) Adverse experiences Inappropriate sexual contact Psychedelics Psychedelic therapy safety +3

The Antidepressant Effects of Vaporized N,N-Dimethyltryptamine: An Open-Label Pilot Trial in Treatment-Resistant Depression.

Psychedelic Medicine March 1, 2025 Marcelo Falchi-Carvalho, Handersson Barros, Raynara Bolcont et al. 16 citations

N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic tryptamine contained in the indigenous ayahuasca brew, has shown antidepressant effects. This open-label clinical trial investigates for the first time the efficacy of vaporized DMT in treatment-resistant depression (TRD). Six TRD patients participated in an open-label, fixed-order, dose-escalation study, receiving a lower (15 mg)...

Adverse Events Should Not Be Surprising in Psychedelic Research.

Psychedelic Medicine March 1, 2025 Rebecca Ehrenkranz, Manish Agrawal, Sandeep M. Nayak et al. 7 citations

Research has demonstrated both risks and benefits to using psychedelics as a therapeutic intervention for a variety of mental health conditions. In recent years, the public discourse around psychedelic treatments has been largely positive and focused on benefits more than risks. We believe the field would benefit from more balanced attention to the risks as well as benefits of psychedelics...

DOI: 10.1089/psymed.2024.0006 (opens in new tab) Full text (opens in new tab) Adverse events Clinical trials Science communication Psychedelics/hallucinogens/entheogens

What is Psychological Support in the Context of Psychedelic Clinical Trials?

Psychedelic Medicine February 7, 2025 Jérémie Richard, Michael Levine 12 citations

The topic of psychological support and psychotherapy in the context of clinical investigations of psychedelic drugs is an often debated, yet predominantly unresolved issue in the field. Psychological support, as a concept, is poorly defined and there appears to be little agreement in the field regarding its essential components, boundaries and limits. While researchers have turned their...

Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders: A Scientometric Analysis

Psychedelic Medicine January 21, 2025 Maria Helha Fernandes-Nascimento, Karine Viana-Ferreira, André Brooking Negrão 2 citations

Background: Psilocybin is a natural alkaloid with therapeutic potential in the treatment of different mental disorders. Bibliometric information on its use is still scattered in the literature. Objective: To investigate the temporal and bibliometric patterns of publications and the specificity of psilocybin in the treatment of mental disorders. Method: Performed a bibliometric analysis using...

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research

Psychedelic Medicine January 20, 2025 Marianna Graziosi, Gabrielle Agin-Liebes, Mary P Cosimano et al. 9 citations

Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for...

The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contemporary Care Models.

Psychedelic Medicine December 2, 2024 Amanda Argot Efthimiou, Amanda M. Cardinale, Agnieszka Kepa 8 citations

Music is deeply rooted in the human experience as well as a fundamental part of psychedelic-assisted therapies (PAT) and entheogenic ceremonies. Although a large body of research exists highlighting the importance of music from rehabilitative, psychological, neurobiological, anthropological, religious, and sociological contexts, there is limited scientific literature regarding the specific...

DOI: 10.1089/psymed.2023.0058 (opens in new tab) Psychedelic therapy Psychedelics Music therapy Music's role +7

Preferences and Attitudes Toward Music in Nonclinical Uses of Psychedelics.

Psychedelic Medicine December 2, 2024 Sara G. Gloeckler, Alexandre Lehmann, Sara de la Salle et al. 4 citations

Background: The resurgent interest in psychedelic-assisted therapy for conditions like depression, end-of-life anxiety, and post-traumatic stress disorder is generating highly promising results. Within this therapeutic context, music's role is multifaceted, seen as a critical environmental component and even akin to a hidden therapist. Contemporary clinical protocols often advocate for music...

DOI: 10.1089/psymed.2024.0003 (opens in new tab) Psychedelic music Entheogenic music Journey music Sonic guidance +13

Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.

Psychedelic Medicine December 1, 2024 Cianna J Piercey, Bethany A. Gray, Angelina Sung et al. 5 citations

Approximately 8.5 million Americans over the age of 12 endorsed past year psychedelic use in 2022, with 1.4 million individuals initiating use during this time. Although emerging evidence indicates there may be beneficial aspects of psychedelic use, there is a need to understand how individuals might mitigate potential risks within nonclinical contexts, such as through the use of protective...

DOI: 10.1089/psymed.2023.0052 (opens in new tab) Full text (opens in new tab) Protective behavioral strategies Harm reduction Safety protocols Safe use +4

General Anesthesia Occludes Ketamine's Antidepressant Response in a Rodent Model of Chronic Stress.

Psychedelic Medicine December 1, 2024 Daniel Markman, Andrzej Z Wasilczuk, Joseph Michael Cichon 2 citations

Psychedelic-induced experiences are thought to play an important role in the therapeutic actions of rapid-acting antidepressants. General anesthesia is one scenario in which patients can be rendered unconscious and masked to the psychedelic treatment, providing a simple yet effective method to examine drug-induced changes in the brain devoid of experiences. Chronically stressed adult C57/BL6...

DOI: 10.1089/psymed.2024.0007 (opens in new tab) Full text (opens in new tab) Antidepressant response Chronic stress Dissociation General anesthesia +6

Low-Dose LSD Alters Early and Late Event-Related Potentials to Emotional Faces.

Psychedelic Medicine December 1, 2024 Connor J Haggarty, Hanna Molla, James Glazer et al. 2 citations

Despite widespread popular interest in the use of low doses of Lysergic acid diethylamide (LSD) to improve mood, little is known about how these doses affect emotional processing in the brain. In this study, we tested the effect of a single low dose of LSD (26 µg) compared with placebo on electroencephalogram (EEG) event-related potentials (ERP: N170, P300 and Mismatch Negativity) in healthy...

Participants’ Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis

Psychedelic Medicine November 26, 2024 Nadav Liam Modlin, Tyler McPhee, Nira Zazon et al. 5 citations

Background: Psychedelics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine are increasingly recognized for their potential therapeutic benefits in treating complex and chronic mental health conditions. Growing public interest in psychedelics may drive increased consumption outside of medically supervised clinical trials. Correspondingly, legality issues and...

DOI: 10.1089/psymed.2024.0027 (opens in new tab) Qualitative research Thematic analysis Qualitative analysis Thematic map

Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder

Psychedelic Medicine November 25, 2024 Noah D Gold, Broc A. Pagni, Petros Petridis et al. 3 citations

Background: Psilocybin can produce long-term changes in personality, personal values, and behavior. Although psilocybin-assisted therapy (PAT) is being actively studied for various psychiatric conditions, its effects on personal values in patients with alcohol use disorder (AUD) remain unexplored. This study examined the effects of PAT on personal values in patients with AUD and assessed...

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder

Psychedelic Medicine November 18, 2024 Shakila Meshkat, Erica Kaczmarek, Zoe Doyle et al. 8 citations

Background: Bipolar II disorder (BD-II) is often associated with chronic and treatment resistant major depressive episodes. Psilocybin has shown promise for its rapid-acting antidepressant effects, though its impact on bipolar depression remains unexplored. In the present subgroup analysis of an already published trial on treatment-resistant depression (TRD), we aimed to preliminarily evaluate...

Systematic Review of the Effect of Psychedelic-Assisted Therapy on Attitudes Toward Death, Life, and Spirituality on Symptoms of Distress, Depression, and/or Anxiety in Patients with Life-Threatening Illness

Psychedelic Medicine October 15, 2024 Thivya Turner, Paul Glue 1 citation

Background: The underlying mechanism(s) of action of psychedelic-assisted therapy (PAT) to reduce distress, depression, and/or anxiety symptoms in life-threatening illness are poorly understood. It has been postulated that addressing death anxiety, and components of spiritual and existential distress, may be mediating factors. Method: This systematic review describes the current evidence base...

Is Personal Experience Essential for Effective Psychedelic Therapists?: The Challenges of Small, Accumulating Therapist Effects.

Psychedelic Medicine September 4, 2024 Mitch Earleywine, Samantha G. Gomez 5 citations

Many authors assert that those who provide psychedelic-assisted therapy (PAT) likely benefit from having personal experiences with psychedelics (PEP) as part of their training. Meta-analytic results confirm advantages of experiential learning in other forms of training as well. Potential PAT clients, especially those who identify as members of underrepresented groups, report that PEP is...

Psychedelic-Assisted Therapy Training: An Argument in Support of Firsthand Experience of Nonordinary States of Consciousness in the Development of Competence.

Psychedelic Medicine September 4, 2024 Shannon Dames, Crosbie Watler, Pamela Kryskow et al. 4 citations

Introduction: This perspective on experiential training delves into the potential benefits and counterarguments related to integrating firsthand experience of psychedelic-assisted therapy (PaT) to enhance the competency of trainees. The Case for Experiential Training as a Core PaT Competency: Experiential training serves a dual purpose: promoting therapists' mental wellness and refining their...

Divergent Effects of Ketamine and the Serotoninergic Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine on Hippocampal Plasticity and Metaplasticity.

Psychedelic Medicine September 1, 2024 Zarmeen Zahid, Ziyad W. Sultan, Bryan M Krause et al. 5 citations

Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that despite having distinct molecular targets, both drugs may exert therapeutic benefit via their pro-neuroplastic effects. Following treatment with ketamine or serotonergic psychedelics, patients are reported to be more open to behavioral change, which...

DOI: 10.1089/psymed.2023.0061 (opens in new tab) Full text (opens in new tab) Psychedelic-therapy Brain-plasticity Mental-health Pharmacology

Nurses' Perceptions of Psychedelics to Address Mental Health Problems in the United States.

Psychedelic Medicine September 1, 2024 Carolyn M. Porta, Madison E. Weirick, Anna Graefe et al. 4 citations

To explore nurses' knowledge, attitudes, and perceived social norms about psychedelic use to address mental health conditions. Data were collected through an anonymous e-survey of Minnesota registered nurses, advanced practice registered nurses, and psychiatric-mental health nurse practitioners in Spring 2023; the pool was randomly selected from the Minnesota Board of Nursing registry. A total...

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.

Psychedelic Medicine September 1, 2024 Crystal Lederhos Smith, Nathan Sackett, Brian Connor Stark et al. 4 citations

There is increasing interest in the use of psychedelics for therapeutic and recreational use. Research has been hindered by federal prohibition, put in place in 1970. Despite the regulatory difficulty, research has rapidly expanded in the past decade. Multiple states and cities have drafted their own policies regarding the use of psychedelics. Assuming interest in psychedelics continues to...

Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.

Psychedelic Medicine September 1, 2024 Michelle St Pierre, Lucas Standing, Yarissa Herman et al. 3 citations

A core component in the provision and receipt of appropriate medical care is trust and communication between patients and physicians. The use of psychedelics for therapeutic purposes (PTPs) has experienced growing attention in the past decade and may be an increasing topic of patient-physician interactions. The stigmatization of psychedelic use may complicate this process. However, patient...

DOI: 10.1089/psymed.2023.0060 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Barriers to access Physician communication Plant medicine +5

The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review.

Psychedelic Medicine September 1, 2024 Banan Ramarushton, Heidemarie Blumenthal, Anthony Ryals et al. 2 citations

Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress disorder). Evidence suggests that rumination is a transdiagnostic process that may play a key role in the comorbidity of such disorders. However, rumination...

DOI: 10.1089/psymed.2024.0009 (opens in new tab) Full text (opens in new tab) Psychedelics Repetitive negative thinking Rumination

Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Psychedelic Medicine

Psychedelic Medicine September 1, 2024 Albert Garcia‐romeu

Rationale: N-methyl-D-aspartate receptor-mediated dissociatives and serotonergic hallucinogens are being increasingly used in therapeutic interventions that involve nonordinary states of consciousness and may represent a unique mental health paradigm wherein pharmacologically induced experiences are conducive to psychological well-being. Objective: The aim of this study was to further...

Perceived Risk of Trying Lysergic Acid Diethylamide in the United States from 2015 to 2019: Are Americans Assessing Lysergic Acid Diethylamide's Risk Profile More Favorably?

Psychedelic Medicine June 1, 2024 Brian S. Barnett, Akhil Anand, Elizabeth N. Dewey et al. 20 citations

Though lysergic acid diethylamide (LSD) use is rising in the United States amid expanding research into the therapeutic potential of psychedelics, little scholarly work exists on whether perceived risk of trying LSD (prLSD) is changing or factors influencing prLSD among the general public. Therefore, we sought to investigate changes in prLSD from 2015 to 2019 and identify characteristics...

DOI: 10.1089/psymed.2023.0027 (opens in new tab) Full text (opens in new tab) LSD Psychedelics hallucinogens Entheogens Harm reduction +5

Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety, and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study.

Psychedelic Medicine June 1, 2024 Ryan Yermus, John Bottos, Nathan Bryson et al. 13 citations

Ketamine-assisted psychotherapy (KAP) is an emerging treatment option to alleviate treatment-resistant affective disorders, but its long-term effectiveness remains unclear. To examine the treatment effects of KAP on anxiety, depression, and post-traumatic stress disorder (PTSD) at 1, 3, and 6 months post-treatment. This retrospective effectiveness study included self-reported outcomes from...